Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2002

View Archived Issues

Elan sells remaining stock in Athena Diagnostics

Better antihyperlipidemic profile reported for metformin plus pioglitazone in type 2 diabetes

Potential use of pirfenidone in progressive renal disease

Renoprotective effects of ALT-711 in diabetic rats

A novel prostate cancer vaccine reported to induce specific immune responses

New data on the immunomodulatory effects of IL-2 + histamine in advanced melanoma

Preclinical and preliminary clinical data reported for Pyridorin

Galapagos Genomics awarded grant for bone disease research

Morphochem enters research collaboration with AstraZeneca for novel antithrombotics

Miravant discusses phase III SnET2 data with FDA

Canadian approval for Thymoglobulin in renal transplant patients

Expanded indication for EmdogainGel in E.U.

Acambis completes phase I trial of dengue vaccine component

Rotigotine CDS reduces symptoms of restless legs syndrome in phase II trial

PDE4 and/or PDE7 inhibitors identified at Altana Pharma

New folate analogues for the delivery of therapeutic and diagnostic agents

Vertex presents novel inhibitors of caspase and TNF-alpha production

Allergan licenses rights to PEP-005 from Peplin Biotech

New series of HDAC inhibitors prepared and tested by Roche researchers

Novel alpha2delta ligands with utility in neuropathic pain and other disorders

Pharmacia claims new alpha7 nicotinic acetylcholine receptor agonists

Chemokine CXCR3 antagonists designed by Millennium and Kyowa Hakko

Phase I IND cleared for LY-674

SRP-299 enters phase II in childhood atopic dermatitis

Cotara receives orphan drug status in E.U.

European Commission grants marketing authorization for Zavesca

CD22-targeted immunoconjugate characterized at EORTC-NCI-AACR meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...